Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I)

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 575-577

  Park, Sung Wook ^a   We, Jeoung Soon ^a   Kim, Gye Won ^a   Choi, Seong Hak ^a   Park, Haeng Soon ^a  

^a Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 HYDROXYETHYL) 2 [2 (3 METHANESULFONYLAMINO 1 PROPENYL) 4 PYRROLIDINYLTHIO] 1 METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CILASTATIN; DEHYDROPEPTIDASE I; DIPEPTIDASE; IMIPENEM; MEROPENEM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; ENZYME SPECIFICITY; ENZYME STABILITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SWINE;

ANIMALS; CARBAPENEMS; DIPEPTIDASES; ENZYME STABILITY; IMIPENEM; SUBSTRATE SPECIFICITY; THIENAMYCINS;

EID: 0036148609     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.575-577.2002     Document Type: Article

References (24)

1. Meropenem: Evaluation of a new generation carbapenem
2. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
3. Specificity and inhibition studies of human renal dipeptidase
4. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I
5. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I
6. Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18632 aerobic bacteria tested in 92 German centers
7. Multicenter in vitro evaluation of SM-7338, a new carbapenem
8. Thienamycin: Development of imipenen-cilastatin
9. β-lactamase activity of renal dipeptidase against N-formimidoyl-thienamycin
10. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rabbits with endotoxin-induced pyrexia
11. Nephroprotective effect of betamipron on a new carbapenem, DA-1131, in rabbits
12. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics
13. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus
14. No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs
15. Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits
16. Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats
17. Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs
18. Pharmacokinetics and tissue distribution of a new carbapenem DA-1131, after intravenous administration to mice, rats, rabbits and dogs
19. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure
20. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I
21. MK0787 (N-formimidoyl thienamycin): Evaluation of in vitro and in vivo activities
22. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin
23. Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa
24. Human renal dipeptidase from kidneys of renal stone patients: Partial purification